Skip to content

A randomized, prospective, comparative study to evaluate the efficacy and safety of diced ADM alone use versus combined use of diced ADM and micronized ADM filler for reconstruction of defect areas after breast conserving surgery in breast cancer patients

A randomized, prospective, comparative study to evaluate the efficacy and safety of diced ADM alone use versus combined use of diced ADM and micronized ADM filler for reconstruction of defect areas after breast conserving surgery in breast cancer patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0008492
Enrollment
100
Registered
2023-06-02
Start date
2023-05-31
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : As a method of filling the defective area after breast conserving surgery, the study group uses a combination of diced type MegaDerm® and MegaFill® (micronized ADM filler), and the co

Sponsors

Kosin University Gospel Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: All subjects can participate in the clinical trial only when all of the following criteria are met. ? Those between the ages of 20 to under 65 years ? Subject who will be get a breast partial resection for breast cancer ? Subject who will be get a oncoplastic breast-conserving surgery using diced MegaDerm® or a combination of diced MegaDerm® and MegaFill® (micronized ADM filler)

Exclusion criteria

Exclusion criteria: If any of the following items apply, the subject is excluded from the clinical trial. Subject who have undergone radiation therapy before surgery Subject who will be get a radiation therapy after surgery Subject who will be get an additional breast surgery due to local recurrence after breast conserving surgery Subject who have an uncontrolled seriously infection Subject who have autoimmune diseases Subject with blood clotting disorders Subject who are judged by medical investigator to be considered unsuitable for this clinical trial

Design outcomes

Primary

MeasureTime frame
Evaluation of cosmetic outcomes by independent evaluators (Aesthetic Items Scale)

Secondary

MeasureTime frame
Evaluation of subject cosmetic satisfaction (10-point scale);Quantitative evaluation of volume changes in ADM used;Evaluation of complications

Countries

Korea, Republic of

Contacts

Public ContactGiryeong Baek

Kosin University Gospel Hospital

ryeongb100@gmail.com+82-51-990-6569

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026